Your TL;DR: TABA used to be treated as a narrow add-on, often vendor-bound and easy to overlook during proposal strategy. The new SBIR/STTR reauthorization makes it more flexible, more operational, and more important than many companies realize. If you still think of TABA as a small line item for outside commercialization advice, you are reading the change too narrowly. It now reaches internal staffing, cybersecurity, training, and foreign involvement screening, which means it has become part of how a company prepares to execute, commercialize, and withstand scrutiny after award.
TABA is no longer a side consideration in proposal strategy
The recent SBIR/STTR reauthorization did more than keep the programs alive through September 30, 2031. It also rewrote the practical meaning of Technical and Business Assistance, or TABA, in a way that serious applicants should not treat as administrative housekeeping. The Small Business Innovation and Economic Security Act revised section 9(q) of the Small Business Act so that agencies must authorize award recipients to select TABA if they want it, expanded the scope of permissible activities, and opened the door for companies to use those funds for internal staffing and training, not just outside vendors.
That matters for a simple reason. TABA has always been framed as support for commercialization and execution, yet many applicants still build proposals as if technical merit lives in one corner and market readiness lives somewhere else. The new language pushes those pieces closer together. A company that understands that shift can budget and justify TABA as part of execution discipline, not as an afterthought attached to the end of a proposal. As teams revisit their internal proposal templates, this is a useful moment to examine whether commercialization planning is actually built into the work, or merely described around it.
The real change is not just more TABA, it is more control over how it gets used
Under the Senate-passed bill text, Congress changed the core TABA structure from an agency entering into agreements with vendors to a model where agencies shall authorize SBIR and STTR award recipients to select TABA, if desired, for their projects. The statutory language also changed the paragraph heading from vendor selection to eligible uses of funds, which is not cosmetic. It signals that Congress wanted TABA to function less like a constrained procurement channel and more like a usable commercialization and execution tool inside the award.
That shift becomes even more concrete in the next section of the law. Small businesses may use TABA funding, by contract or otherwise, to hire new staff, augment staff, or direct staff to conduct or participate in training activities consistent with TABA goals. Congress also preserved the familiar funding caps, up to $6,500 for Phase I and up to $50,000 for Phase II.
For experienced applicants, the practical takeaway is larger than the dollar figure. This is no longer just a question of which outside consultant or commercialization vendor might be worth retaining. TABA can now support internal capacity in a way that better matches how real companies execute. While some teams need a regulatory consultant, others need cybersecurity support or to train staff who will carry the commercialization burden themselves. The law now recognizes that those are not side issues. They are part of whether the innovation can move forward responsibly.
Congress expanded what TABA is supposed to cover, and that changes proposal positioning
The updated statute added cybersecurity assistance to the list of supported purposes and added screening for potential foreign involvement in technology development or commercialization activities. NIH has already translated that shift into policy language, explaining that TABA is intended to support better technical decisions, reduce technical risk, commercialization activities, intellectual property protection, and screening for potential foreign involvement in technology development or commercial activities. NIH also states that applicants and recipients may use TABA for staff, vendors, consultants, or subawards, depending on the activity.
This is where many companies will underread the statute. They will notice the reauthorization, note that TABA still exists, keep using old assumptions, and move on. The gap is that the law now treats TABA as part of both commercialization readiness and risk management, while many applicants still prepare budgets as if those functions are separate, optional, or too minor to warrant careful consideration.
That mismatch has consequences. A weak TABA request is no longer just a missed chance to fund a market report. It can signal that the company has not carefully considered who will handle cybersecurity questions, how commercialization decisions will be made, whether risks associated with foreign involvement have been evaluated, or what internal capacity is required to move the project toward Phase II, Phase III, or private-market traction. A proposal does not become stronger merely by naming those issues, though it becomes more credible when the budget and narrative show the company knows where execution pressure will actually fall.
TABA now overlaps more directly with commercialization training, including I-Corps
The bill also added an I-Corps participation provision for federal agencies that operate an Innovation Corps program. Those agencies must provide an option for SBIR or STTR award recipients to request participation in an I-Corps course, bootcamp, or equivalent training program, and recipients may use TABA-authorized amounts for that participation. The statute even identifies multiple permissible sources for participation costs, including TABA funds under subsection (q).
That is an important signal from Congress. Agencies are not being nudged to treat customer discovery, commercialization training, and technical execution as separate worlds. They are being pushed toward a more integrated model. NIH has already reflected that approach by listing participation in NIH I-Corps among the activities TABA funding can support.
For founders and research teams, this means TABA planning should start earlier. It belongs in proposal design, work allocation, and commercialization sequencing. Teams that wait until after the award to ask what TABA might cover often miss the deeper strategic question, which is whether the proposed work already reflects the staffing, market learning, and risk-review activities the project will actually require. That is often the point in the process at which EBHC advises companies to pressure-test whether the commercialization plan is operational enough to withstand agency review and post-award execution.
NIH has already shown what implementation looks like, and it is more flexible than many applicants expect
NIH issued a policy notice on April 20, 2026, after the Act was signed into law on April 13, 2026, confirming that SBIR and STTR recipients may request up to $6,500 per Phase I project and $50,000 per Phase II project across all years, and may meet TABA goals either by selecting vendors or by hiring new staff, augmenting staff, or directing staff to training activities. The agency also states that recipients may request TABA funding in the application and, if needed later, through an administrative supplement, subject to the discretion of the institute and center.
That last point deserves more attention than it usually gets. Once an agency begins implementing the statutory changes, TABA becomes something a company can use to adjust to real execution needs after award, not only something locked into the original application narrative. Even so, companies should not read that flexibility as permission to be vague on the front end. Agencies are far more comfortable with post-award adjustments when the original application already shows coherent thinking about commercialization, operational burden, and risk.
A company that expects to need TABA should build that expectation into the proposal’s logic, not just the budget pages. That usually produces cleaner justifications, stronger reviewer confidence, and fewer internal contradictions once the project moves from idea to funded work.
Why this matters now
There is a habit in the SBIR/STTR market of treating smaller statutory changes as technical notes for grants administrators. That reading misses what Congress appears to be doing here. TABA is being repositioned as a more practical bridge between R&D, commercialization, training, compliance awareness, and internal execution capacity.
Teams that keep using the old mental model may still submit compliant requests, yet they are more likely to under-budget, under-justify, or outsource the wrong functions. Those who read the change correctly can make sharper decisions about what should stay in the company, what belongs with a vendor, and how to explain those choices in a way that aligns with how agencies increasingly view readiness. As you revisit proposal development for upcoming SBIR or STTR opportunities, it is worth asking whether your TABA plan reflects how your company will really execute, not just what used to fit neatly into a legacy template.
Closing thoughts
The most important change in TABA is not that Congress kept it alive. The important change is that Congress made it more usable, more operational, and more closely tied to the realities of commercialization and program risk. That is good news for companies that are building serious internal capacity. It is less forgiving for companies still treating commercialization support as decorative language around a technical project.
When TABA is framed correctly, it stops being a small optional add-on and starts becoming evidence that a company understands what it takes to move an innovation through the federal funding system with discipline. That is the level at which this change should be read, and it is the level at which proposal strategy should now respond. For companies evaluating how these statutory changes should alter budget structure, commercialization planning, and post-award execution choices, a more exact reading of TABA can prevent expensive mistakes before they get embedded in the application.
Ready To Take the Next Step?
We assist our clients in locating, applying for, and evaluating the outcomes of non-dilutive grant funding. We believe non-dilutive funding is a crucial tool for mitigating investment risks, and we are dedicated to guiding our clients through the entire process—from identifying the most suitable opportunities to submitting and managing grant applications.